ArticleOncotarget2017

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.

Zhijie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.